Picton Mahoney Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Picton Mahoney Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-365,000	Closed	-$48.2M	–	1228
2025 Q1	$48.2M	Buy	365,000 +364,928	+506,844%	+$45.5M	0.83%	12
2024 Q4	$6K	Buy	72 +26	+57%	+$2.14K	﹤0.01%	568
2024 Q3	$3K	Sell	46 -74	-62%	-$5.56K	﹤0.01%	565
2024 Q2	$8K	Buy	+120	New	+$8.32K	﹤0.01%	502

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Picton Mahoney Asset Management's ITCI Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 365,000 shares — an estimated $48.2M sold.

Picton Mahoney Asset Management first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $48.2M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Picton Mahoney Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Picton Mahoney Asset Management sold 365,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $48.2M.
Picton Mahoney Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Picton Mahoney Asset Management's Intra-Cellular Therapies Inc. position peaked at $48.2M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.